Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review

Hepatology Research

Volumn 45, Issue 1, 2015, Pages 59-74

  Osaki, Yukio ^a   Nishikawa, Hiroki ^a  

^a NONE

Author keywords

Hepatocellular carcinoma; Progress; Surveillance; Three decades; Treatment

Indexed keywords

SORAFENIB;

ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CHEMOEMBOLIZATION; HIGH RISK POPULATION; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 84921023992     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12378     Document Type: Article

References (118)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.
2. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-773.
3. Nishikawa H, Osaki Y. Non-B, non-C hepatocellular carcinoma (Review). Int J Oncol 2013; 43 (5): 1333-1342.
4. Llovet JM. Update treatment approach to hepatocellular carcinoma. J Gastoenterology 2005; 40: 225-235.
5. Llovet JM, Ricci S, Mazzaferro V etal.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
6. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
7. van Meer S, de Man RA, Siersema PD, van Erpecum KJ. Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies. World J Gastroenterol 2013; 19 (40): 6744-6756.
8. Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist 2010; 15 (Suppl 4): 23-33.
9. Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2012; 6 (2): 173-185.
10. Lencioni R, Crocetti L. Image-guided ablation for hepatocellular carcinoma. Recent Results Cancer Res 2013; 190: 181-194.
11. Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012; 39 (4): 503-509.
12. Duan F, Lam MG. Delivery approaches of gene therapy in hepatocellular carcinoma. Anticancer Res 2013; 33 (11): 4711-4718.
13. Miamen AG, Dong H, Roberts LR. Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer 2012; 1 (3-4): 226-237.
14. Hankey BF, Ries LA, Kosary CL etal. Partitioning linear trends in age-adjusted rates. Cancer Causes Control 2000; 11: 31-35.
15. Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013; 4 (8): 635-643.
16. Ministry of Health. Labour and Welfare. Abridged Life Tables for Japan 2006 (2006). Available at: http://www.mhlw.go.jp/english/database/db-hw/lifetb06/index.html. Accessed March 20, 2014.
17. Kiyosawa K, Tanaka E. Characteristics of hepatocellular carcinoma in Japan. Oncology 2002; 62 (Suppl 1): 5-7.
18. Ikai I, Arii S, Okazaki M etal.; The Liver Cancer Study Group of Japan, Kyoto, Japan. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-691.
19. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53 (1): 39-43.
20. Tanaka H, Imai Y, Hiramatsu N etal. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008; 148 (11): 820-826.
21. Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol 2011; 46: 1230-1237.
22. Kaibori M, Ishizaki M, Matsui K, Kwon AH. Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg 2012; 204: 300-307.
23. Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol 2008; 43: 967-974.
24. Nagaoki Y, Hyogo H, Aikata H etal. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res 2012; 42: 368-375.
25. Suzuki Y, Ohtake T, Nishiguchi S etal.; The Japan Non-B, Non-C Liver Cirrhosis Study Group. Survey of non-B, non-C liver cirrhosis in Japan. Hepatol Res 2013; 43 (10): 1020-1031.
26. Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20 (7): 1712-1723.
27. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
28. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int 2013; 33 (Suppl 1): 93-104.
29. Kwon H, Lok AS. Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther 2011; 16 (6): 787-795.
30. Singal AK, Singh A, Jaganmohan S etal. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8 (2): 192-199.
31. Donato F, Tagger A, Gelatti U etal. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155 (4): 323-331.
32. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008; 75 (Suppl 1): 1-12.
33. Nouso K, Ito Y, Kuwaki K etal. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer 2008; 98 (7): 1161-1165.
34. Kudo M, Izumi N, Kokudo N etal.; HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364.
35. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014; 11 (4): e1001624.
36. Mazzaferro V, Romito R, Schiavo M etal.; HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554.
37. Nishikawa H, Nishijima N, Arimoto A etal. Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Res 2013; 31: 4167.
38. Toyoda H, Kumada T, Tada T, Sone Y, Fujimori M. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. J Vasc Interv Radiol 2012; 23 (3): 317-322.
39. Kubo S, Takemura S, Sakata C, Urata Y, Uenishi T. Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus. Liver Cancer 2013; 2 (1): 40-46.
40. Makuuchi M, Donadon M, Torzilli G. Hepatic resection for hepatocellular carcinoma in cirrhosis. Ann Ital Chir 2008; 79 (2): 111-115.
41. European Association for The Study Of The Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (4): 908-943.
42. Jarnagin WR, Gonen M, Fong Y etal. Improvement in perioperative outcome after hepatic resection: analysis of 1, 803 consecutive cases over the past decade. Ann Surg 2002; 236: 397-406.
43. Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg 2006; 244 (2): 265-273.
44. Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection - 2, 804 patients. Ann Surg 2009; 250: 831-841.
45. Nguyen KT, Marsh JW, Tsung A etal. Comparative benefits of laparoscopic vs open hepatic resection: a critical appraisal. Arch Surg 2011; 146: 348-356.
46. Eguchi S, Kanematsu T, Arii S etal.; Liver Cancer Study Group of Japan. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008; 143 (4): 469-475.
47. Mazzaferro V, Regalia E, Doci R etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
48. Chan SC. Liver Transplantation for Hepatocellular Carcinoma. Liver Cancer 2013; 2 (3-4): 338-344.
49. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765-774.
50. Kaido T, Ogawa K, Mori A etal. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery 2013; 154 (5): 1053-1060.
51. Takayasu K, Arii S, Ikai I etal.; Liver Cancer Study Group of Japan. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010; 194 (3): 830-837.
52. Doyon DMA, Jourde AM, Regensberg C, Frileux C. L'embolisation arterielle hepatique dans les tumeurs malignes du foie. Ann Radiol 1974; 17: 593-603.
53. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148 (2): 397-401.
54. Yumoto Y, Jinno K, Tokuyama K etal. Hepatocellular carcinoma detected by iodized oil. Radiology 1985; 154: 19-24.
55. Ohishi H, Uchida H, Yoshimura H etal. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology 1985; 154: 25-29.
56. Llovet JM, Real MI, Montaña X etal.; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319): 1734-1739.
57. Lo CM, Ngan H, Tso WK etal. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (5): 1164-1171.
58. Cammà C, Schepis F, Orlando A etal. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224 (1): 47-54.
59. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
60. Takayasu K, Arii S, Ikai I etal.; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131 (2): 461-469.
61. Varela M, Real MI, Burrel M etal. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 30 (1): 474-481.
62. Lammer J, Malagari K, Vogl T etal.; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 30 (1): 41-52.
63. Vogl TJ, Lammer J, Lencioni R etal. Liver, gastrointestinal and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011; 30 (1): W562-570.
64. Ebara M, Ohto M, Sugiura N etal. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 1990; 5 (6): 616-626.
65. Lencioni RA, Allgaier HP, Cioni D etal. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228 (1): 235-240.
66. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4cm. Gastroenterology 2004; 127 (6): 1714-1723.
67. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less. Gut 2005; 54 (8): 1151-1156.
68. Shiina S, Teratani T, Obi S etal. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129 (1): 122-130.
69. Hong SN, Lee SY, Choi MS etal. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well preserved hepatic function. J Clin Gastroenterol 2005; 39 (3): 247-252.
70. Montorsi M, Santambrogio R, Bianchi P etal. Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J Gastrointest Surg 2005; 9 (1): 62-67.
71. Cho CM, Tak WY, Kweon YO etal. The comparative results of radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma. Korean J Hepatol 2005; 11 (1): 59-71.
72. Ogihara M, Wong LL, Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB (Oxford) 2005; 7 (3): 214-221.
73. Lu MD, Kuang M, Liang LJ etal. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi 2006; 86 (12): 801-805.
74. Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A, Memeo V. Single hepatocellular carcinoma ranging from 3 to 5cm: radiofrequency ablation or resection? HPB (Oxford) 2007; 9 (6): 429-434.
75. Hasegawa K, Makuuchi M, Takayama T etal. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 2008; 49 (4): 589-594.
76. Guglielmi A, Ruzzenente A, Valdegamberi A etal. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2008; 12 (1): 192-198.
77. Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ, Pearce NW, Nicoli N. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg 2008; 12 (9): 1521-1526.
78. Ueno S, Sakoda M, Kubo F etal. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. J Hepatobiliary Pancreat Surg 2009; 16 (3): 359-366.
79. Zhou Y, Zhao Y, Li B etal. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol 2010; 10: 78.
80. Sala M, Llovet JM, Vilana R etal. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40 (6): 1352-1360.
81. Osaki Y, Ikeda K, Izumi N etal. Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers. J Gastroenterol 2013; 48 (11): 1308-1309.
82. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2011; 98 (9): 1210-1224.
83. Nishikawa H, Osaki Y, Iguchi E etal. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol 2013; 48 (8): 951-965.
84. Fan ST, Mau Lo C, Poon RT etal. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011; 253 (4): 745-758.
85. Nishikawa H, Kimura T, Kita R, Osaki Y. Radiofrequency ablation for hepatocellular carcinoma. Int J Hyperthermia 2013; 29 (6): 558-568.
86. Schwartz ME, Shrager B. Surgical resection for hepatocellular carcinoma in the noncirrhotic: the Western experience. Recent Results Cancer Res 2013; 190: 85-100.
87. Chen MS, Li JQ, Zheng Y etal. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243 (3): 321-328.
88. Huang J, Yan L, Cheng Z etal. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903-912.
89. Feng K, Yan J, Li X etal. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57 (4): 794-802.
90. Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010; 51 (4): 1284-1290.
91. Hasegawa K, Kokudo N, Makuuchi M etal. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013; 58 (4): 724-729.
92. Osaki Y, Ueda Y, Marusawa H etal. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. J Gastroenterol 2012; 47 (4): 444-451.
93. Shiratori Y, Shiina S, Teratani T etal. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138 (4): 299-306.
94. Nishikawa H, Osaki Y, Iguchi E etal. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol 2013; 47 (4): 359-366.
95. Hasegawa K, Kokudo N, Shiina S, Tateishi R, Makuuchi M. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: start of a randomized controlled trial (SURF trial). Hepatol Res 2010; 40 (8): 851-852.
96. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
97. Kudo M. Targeted therapy for liver cancer: updated review in 2012. Curr Cancer Drug Targets 2012; 12: 1062-1072.
98. Nishikawa H, Osaki Y, Kita R, Kimura T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Cancers 2012; 4: 165-183.
99. Johnson PJ, Qin S, Park JW etal. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31: 3517-3524.
100. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410-1426.
101. Pazo-Cid RA, Lanzuela M, Esquerdo G etal. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 2012; 14: 564-574.
102. Takeda H, Nishikawa H, Osaki Y etal.; Japanese Red Cross Liver Study Group. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int 2014; [Epub ahead of print].
103. Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol 2014; 91: 1-8.
104. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 2012; 17 (3): 359-366.
105. Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 2011; 81 (Suppl 1): 50-55.
106. Wang Z, Zhang G, Wu J, Jia M. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect. Drug Discov Ther 2013; 7 (4): 137-143.
107. Shen YC, Lin ZZ, Hsu CH, Hsu C, Shao YY, Cheng AL. Clinical trials in hepatocellular carcinoma: an update. Liver Cancer 2013; 2 (3-4): 345-364.
108. Ando E, Tanaka M, Yamashita F etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95 (3): 588-595.
109. Ueshima K, Kudo M, Takita M etal. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010; 78: S148-153.
110. Obi S, Yoshida H, Toune R etal. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106 (9): 1990-1997.
111. Xi M, Zhang L, Zhao L etal. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013; 8 (5): e63864.
112. Nakazawa T, Hidaka H, Shibuya A etal. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol 2014; 14 (1): 84.
113. Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012; 56 (2): 464-473.
114. Mazzaferro V, Sposito C, Bhoori S etal. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013; 57 (5): 1826-1837.
115. Moreno-Luna LE, Yang JD, Sanchez W etal. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 2013; 36 (3): 714-723.
116. Cheng JW, Lv Y. New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol 2013; 30 (1): 381.
117. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007; 23: 175-205.
118. Greene CM, Varley RB, Lawless MW. MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled. World J Gastroenterol 2013; 19 (32): 5212-5226.